Fujitsu Limited, Kyoto University, Chordia Therapeutics, Inc., have announced the beginning of field trials leveraging Fujitsu’s AI causal discovery technology to shed light on biomarkers that increase the probability of success or shorten the duration of clinical trials in the development of new cancer drugs.
Using results obtained from Kyoto University’s next-generation sequencer platform for analysing genomic information and Fujitsu’s causal discovery technology on its “Fujitsu Kozuchi (code name) – Fujitsu AI Platform” where advanced AI technologies can be tested, this project will investigate causal structures and the conditions under which these structures occur in the drug effect and the estimated 20,000 genes that compose the human genome. This information will assist researchers working to discover biomarkers for patient stratification that can be used to determine the efficacy of cancer treatments that target RNA regulatory stress, under development by Kyoto University and Chordia since May 2018.
Through this demonstration, Fujitsu, Kyoto University, and Chordia Therapeutics aim to realise new cancer treatments personalised to individual patients’ genetic characteristics, cancer symptoms and progression, ultimately improving patient outcomes and well-being.
Seishi Ogawa, professor, Graduate School of Medicine, Kyoto University, comments “We have built this genome information analysis platform equipped with next-generation sequencers to analyse the nature of cancer and discover clues that may one day lead to the creation of new drugs. In collaboration with this platform, and by leveraging the causal discovery technology on Fujitsu’s new AI platform, we aim to create next-generation cancer genome analysis technology with unique capabilities to accelerate drug development.”
Daisuke Morishita, CSO, Chordia Therapeutics, Inc., comments “The identification and use of biomarkers that support drug development play an important role in determining the success of clinical trials when we’re developing new drugs. We are eager to embark on this collaboration with Fujitsu and Kyoto University, which will allow us to further explore biomarkers for promising new drugs under development.”
Seishi Okamoto, EVP, head of Fujitsu Research, Fujitsu Limited, comments “In April 2023, Fujitsu announced the global launch of its new AI platform, code-named “Kozuchi.” The platform offers users in a range of industries and fields the ability to rapidly test promising applications using advanced AI technologies. This project demonstrates the innovative capabilities of the causal discovery technology provided by the platform, and we are optimistic that this trial will offer a positive impact on patient well-being and medical research as an example of how industry and academia can work together, as well as strong use case for other potential users of Kozuchi.”
Follow us and Comment on Twitter @TheEE_io